CASI Pharmaceuticals Inc. CASIF
0.13
(0.03)
(18.75%)
as of 25 Sep
- Market cap
- $12.4M
- P/E
- 0.0×
Follow CASIF
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 271.28% | 669.76% | 830.72% |
+8 more TTM periods Free account |
|
| 0.00% | (121.17%) | (112.12%) | (113.71%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 164.33% | 242.48% | 385.20% | |
Average Days of Receivables |
0.00 | 72.11 | 35.47 | 62.02 | |
Free Cash Flow per Share |
— | (4.83) | 0.00 | 0.00 | |
Free Cash Flow |
— | (89.59) | — | — | |
Capital Expenditures |
— | (1.55) | — | — | |
Piotroski F-Score |
— | 0.00 | — | — | |
| Other line items | |||||
Cash ROIC |
0.00% | 1,071.38% | 0.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 2.13 | 3.90 | 4.82 | |
Accounts Payable Turnover |
0.00 | 5.62 | 14.83 | 23.31 | |
Inventory Turnover |
0.00 | 3.11 | 2.22 | 2.07 | |
Average Days of Payables |
0.00 | 36.55 | 11.86 | 15.79 | |
Days of Inventory on Hand |
0.00 | 54.84 | 55.30 | 66.61 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 30.46% | 32.55% | 28.03% | |
Selling, General and Administrative Expense of Revenue |
— | 225.06% | 165.46% | 144.13% | |
Share Based Compensation of Revenue |
— | 62.42% | 0.00% | 0.00% | |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 1.83 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 1.18 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.19) | — | — | |
Revenue per Share |
— | 1.12 | 1.67 | 2.04 | |
Operating CF per Share |
— | (4.75) | 0.00 | 0.00 | |
Capex per Share |
— | (0.08) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.07 | 0.00 | 0.00 | |
Net Profit Margin |
— | (232.03%) | (183.93%) | (148.56%) |
Columns are period end dates